Clinical Trials

Our team of myeloma experts develop and oversee clinical trials from inception to completion. Since our founding, over 350 patients have received myeloma treatment through one of our 9 multi-centre clinical trials. Our portfolio of clinical trials continues to grow each year.

CMRG 001

Status:  Open, closed for enrolment

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

The Phase II trial combines selinexor, with dexamethasone and a “backbone” therapy: either bortezomib (Velcade®), lenalidomide (Revlimid®) or pomalidomide (Pomalyst®) in patients with relapsed or refractory myeloma. The therapies are given orally, with the exception of bortezomib, which is given by subcutaneous injection.

This trial is in collaboration with Karyopharm Therapeutics.

Lead PI: Dr. Donna Reece

ClinicalTrials.gov Identifier NCT01702831

Participating Sites:

  • Edmonton – Cross Cancer Institute
  • Halifax – Queen Elizabeth II Health Sciences Centre
  • London – London Health Science Centre
  • Montreal – McGill University Health Centre
  • Montreal – Hôpital Maisonneuve-Rosemont
  • Ottawa – The Ottawa General Hospital
  • Saint John – Saint John Regional Hospital
  • Saskatoon – Saskatoon Cancer Centre
  • Toronto – Princess Margaret Hospital
  • Vancouver – Vancouver General Hospital

CMRG 002

Status:  Open, actively recruiting

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

The Phase II trial combines selinexor, with dexamethasone and a “backbone” therapy: either bortezomib (Velcade®), lenalidomide (Revlimid®) or pomalidomide (Pomalyst®) in patients with relapsed or refractory myeloma. The therapies are given orally, with the exception of bortezomib, which is given by subcutaneous injection.

This trial is in collaboration with Karyopharm Therapeutics.

Lead PI: Dr. Nizar Bahlis and Dr. Christine Chen

ClinicalTrials.gov Identifier NCT02343042

Participating Sites:

  • Calgary – Tom Baker Cancer Centre
  • Edmonton – Cross Cancer Institute
  • Halifax – Queen Elizabeth II Health Sciences Centre
  • Montreal – Maisonneuve-Rosemont Hospital
  • Montreal – Royal Victoria Hospital/McGill University
  • Regina – Saskatchewan Cancer Agency – Allan Blair Cancer Centre
  • St John’s – Memorial Hospital of Newfoundland
  • Toronto – Princess Margaret Cancer Centre
  • Vancouver – Vancouver General Hospital
  • Winnipeg – CancerCare Manitoba

CMRG 003

Status:  Closed

A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies

The currently approved dosing schedule for carfilzomib is twice weekly. This trial is evaluating a once-weekly dosing regimen that is more convenient for the patient and is also more cost-effective. The overall lower cost of this combination may help influence provincial drug funding decisions in the future.

Lead PI: Dr. Christopher Venner

ClinicalTrials.gov Identifier NCT02597062

Participating Sites:

  • A special mention goes to the Cross Cancer Institute, Hôpital Maisonneuve-Rosemont and the Ottawa Hospital Research Institute who collectively accounted for more than half of total patient accrual.
  • Edmonton – Cross Cancer Institute
  • Halifax – Queen Elizabeth II Health Sciences Centre
  • Kingston – Kingston General Hospital
  • London – London Health Sciences Centre
  • Montreal – Hôpital Maisonneuve-Rosemont
  • Ottawa – The Ottawa General Hospital
  • Quebec City – Pavillon Hôtel-Dieu de Québec
  • Saint John – Saint John Regional Hospital
  • Toronto – Princess Margaret Cancer Centre

CMRG 004

Status:  Closed

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma

This open-label trial is planned to recruit a total of 120 patients across Canada into two study arms. One group will receive daratumumab, cyclophosphamide, dexamethasone and pomalidomide (Pomalyst®). The other group will receive the same treatment regimen, however pomalidomide will only be added when the participant’s disease progresses.

Lead PI: Dr. Michael Sebag

ClinicalTrials.gov Identifier NCT03215524

Participating Sites:

  • Calgary – Tom Baker Cancer Centre
  • Edmonton – Cross Cancer Institute
  • Halifax – Queen Elizabeth II Health Sciences Centre
  • Hamilton – Juravinski Cancer Centre
  • Ottawa – Ottawa General Hospital
  • Saint John – Saint John Regional Hospital
  • Saskatoon – Saskatoon Cancer Centre
  • Surrey – BCCA Fraser Valley Centre
  • Thunder Bay – Thunder Bay Regional HSC
  • Toronto – Princess Margret Cancer Centre
  • Winnipeg – CancerCare Manitoba

CMRG 005

Status:  Open, actively recruiting

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

The study will compare the combination of selinexor, bortezomib (Velcade®) and dexamethasone (SVd) versus the combination bortezomib and dexamethasone (Vd) in patients with relapsed or refractory myeloma who have had 1-3 prior lines of therapy.

Lead PI: Dr. Nizar Bahlis

ClinicalTrials.gov Identifier NCT03110562

Participating Sites:

  • Calgary – Tom Baker Cancer Centre
  • Edmonton – Cross Cancer Institute
  • Halifax – Queen Elizabeth II Health Sciences Centre
  • Montreal – Hôpital Maisonneuve-Rosemont
  • Montreal – Royal Victoria Hospital/McGill University
  • Quebec City – Pavillon Hôtel-Dieu de Québec
  • Toronto – Princess Margaret Cancer Centre
  • Saskatoon – Saskatoon Cancer Centre
  • Vancouver – Vancouver General Hospital
  • Sudbury – Northeast Cancer Centre, Health Sciences North

CMRG 006

Status:  Open, actively recruiting

A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation

This is a phase 2A, pilot study of Pembrolizumab administered in combination with CyBorD in newly diagnosed, transplant ineligible multiple myeloma patients who achieve less than VGPR (according to IMWG criteria) after two cycles of treatment.

Lead PI: Dr. Rami Kotb

ClinicalTrials.gov Identifier NCT04258683

Participating Sites:

  • Winnipeg – CancerCare Manitoba
  • Moncton – The Moncton Hospital
  • Sherbrooke – CIUSSS de L’Estrie-CHUS
  • Regina – Allan Blair Cancer Centre

CMRG 007

Status:  Open, actively recruiting

A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination with PO Pomalidomide and Low-Dose Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma

Lead PI: Dr. Suzanne Trudel

ClinicalTrials.gov Identifier NCT03715478

This trial is a phase 1 and 2, single-arm, open-label, dose-escalation study that will evaluate the safety and efficacy of GSK2857916 in combination with pomalidomide and low-dose dexamethasone in subjects with relapsed and/or refractory multiple myeloma. Phase 1 will determine the recommended dosage, while Phase 2 will determine the efficacy of GSK2857916

Participating Sites:

  • Halifax – Queen Elizabeth II Health Sciences Centre
  • Ottawa – Ottawa General Hospital
  • Hamilton – Juravinski Cancer Centre
  • London – London Health Sciences Centre
  • Toronto – Princess Margaret Cancer Centre
  • Winnipeg – CancerCare Manitoba
  • Regina – Allan Blair Cancer Centre
  • Edmonton – Cross Cancer Institute
  • Vancouver – Vancouver General Hospital

CMRG 009

Status:  Closed

A Phase 2 Open Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

Lead PI: Dr. Julie Stakiw

ClinicalTrials.gov Identifier NCT03697629

In this Phase II trial, patients with relapsed and/or refractory multiple myeloma will receive an accelerated infusion of daratumumab over a six-month time frame. Patients will be monitored to determine the incidence of infusion related reactions during the initial six months of daratumumab administration.

Participating Sites:

  • Montreal – Hôpital Maisonneuve-Rosemont
  • Montreal – Royal Victoria Hospital/ McGill University
  • Kingston – Kingston General Hospital
  • Toronto – Princess Margaret Cancer Centre
  • Saskatoon – Saskatoon Cancer Agency
  • Quebec City – Hopital de L’Enfant Jesus